Optimizing outcome for patients with mantle cell lymphoma
10.3760/cma.j.issn.1009-9921.2012.07.001
- VernacularTitle:套细胞淋巴瘤治疗方案的选择和建议
- Author:
Huaqing WANG
- Publication Type:Journal Article
- Keywords:
Lymphoma,mantle-cell;
Targeted therapy;
Antitumor drugs
- From:
Journal of Leukemia & Lymphoma
2012;21(7):385-389
- CountryChina
- Language:Chinese
-
Abstract:
Intensive multidrug regimens,such as rituximah plus fractionated cyclophsphamide,vincristine,doxorubicin,and dexamethasone(R-HyperCVAD),are now being used to improve outcomes in patients with mantle cell lymphoma(MCL).In addition to these combinations,novel targeted agents,including bortezomib,bendamustine,and lenalidomide,are also being integrated into the treatment paradigm.Given the wide array of therapies available,making and implementing treatment decisions has become a complex process,requiring interdisciplinary collaboration.This article discussesed the pharmacist's role in this collaboration,as well as the administration of standard and novel therapies for MCL and the management of treatment related toxicities.
